Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
29 May 2014 - 10:00PM
Galectin Therapeutics Inc. (Nasdaq:GALT), the
leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today announced that the Company will
present at the Jefferies 2014 Global Healthcare Conference, to be
held June 2-5, 2014, in New York, NY. Dr. Harold H. Shlevin, Chief
Operating Officer and Corporate Secretary of Galectin Therapeutics,
will provide an overview of the Company's business and recent and
upcoming milestones during his live presentation.
The Jefferies Global Healthcare Conference features
an extensive range of public and private healthcare companies
across the biopharmaceuticals, life sciences, healthcare services,
healthcare information technology and medical technology sectors.
Leading executives, institutional investors, private equity
investors and venture capital firms will address near- and
long-term investment opportunities and discuss the driving forces
in the healthcare industry.
WHAT: Galectin Therapeutics presentation at
Jefferies 2014 Global Healthcare Conference
WHO: Presentation by Dr. Harold Shlevin,
Chief Operating Officer, Galectin Therapeutics
WHEN: Monday, June 2, 2014, 11 a.m. Eastern
Daylight Time
Dr. Shlevin's presentation will be webcast live at
http://wsw.com/webcast/jeff82/galt/. The archived webcast will be
available for 90 days following the presentation.
For more information on the Jefferies 2014 Global
Healthcare Conference, please visit
http://www.jefferies.com/OurFirm/Conferences/325/148
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing
promising carbohydrate-based therapies for the treatment of
fibrotic liver disease and cancer based on the Company's unique
understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development
expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are
pursuing a clear development pathway to clinical enhancement and
commercialization for our lead compounds in liver fibrosis and
cancer. Additional information is available at
www.galectintherapeutics.com.
CONTACT: Galectin Therapeutics Inc.
Dr. Harold H. Shlevin (678)-615-3213
Chief Operating Officer
shlevin@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2024 to May 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2023 to May 2024